Patents by Inventor Richard B. Gaynor

Richard B. Gaynor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240366754
    Abstract: The present disclosure provides pharmaceutical compositions for delivery of viral antigens (e.g., a viral vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
    Type: Application
    Filed: October 14, 2022
    Publication date: November 7, 2024
    Inventors: Richard B. Gaynor, Michael Steven Rooney, Asaf Poran, Theresa Addona, Scott Goulding, Ekaterina Esaulova, Miles Kirsch, Yunpeng Liu, Lauren Stopfer
  • Publication number: 20230141371
    Abstract: Compositions and methods for the prevention and/or treatment of a viral infection, in particular of the Coronaviridae family.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 11, 2023
    Inventors: Richard B. Gaynor, Lakshmi Srinivasan, Asaf Poran, Dewi Harjanto, Christina Kuksin, Daniel Abram Rothenberg, John Srouji
  • Publication number: 20230083931
    Abstract: Compositions and methods for the prevention and/or treatment of a viral infection, in particular of the Coronaviridae family.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 16, 2023
    Inventors: Richard B. Gaynor, Lakshmi Srinivasan, Asaf Poran, Dewi Harjanto, Christina Kuksin, Daniel Abram Rothenberg, John Srouji, Stefanie Krumm, Kaushik Thanki
  • Publication number: 20030032649
    Abstract: The present invention relates to chimeric protein kinase molecules and methods for designing inhibitors of protein kinases using the chimeric protein kinases of the present invention. The chimeric protein kinase of the present invention comprise inhibitor binding site residues of a non-crystallizable protein and non-inhibitor binding site residues of a crystallizable protein. The chimeric protein is preferably crystallizable and is useful for designing inhibitors for the non-crystallizable protein. In addition, the present invention is directed to a protein kinase inhibitor binding site which is outside the ATP binding site of the protein kinase and methods of use therefore.
    Type: Application
    Filed: July 31, 2001
    Publication date: February 13, 2003
    Inventors: Elizabeth J. Goldsmith, Akella Radha, Richard B. Gaynor
  • Patent number: 5994108
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV. Also provided are cell lines that express enhanced levels of TAR mutant viruses relative to other TAR mutant infected cell lines. Levels of production are enhanced by the use of cell lines that express a transactivator protein, such as adenovirus transactivator EIA and/or EIB protein.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: November 30, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard B. Gaynor, David Harrich
  • Patent number: 5688511
    Abstract: Compositions including a polypeptide or nucleic acid sequence encoding a polypeptide that binds TAR DNA (particularly the region -18 to +28 of HIV-LTR DNA) and that does not bind to TAR RNA (particularly the region +1 to +80 of the TAR RNA) are disclosed. The cellular binding protein TDP-43 including the polypeptide has an estimated molecular weight of between about 40 kD and 46 kD as determined by SDS polyacrylamide gel electrophoresis. Fusion proteins that include the entire cellular binding protein TDP-43 or fragments thereof are also described. The cellular binding protein, peptide fragments and nucleic acid sequences encoding them, repress HIV gene expression. Methods for preparing the cellular binding protein from cells as recombinant proteins with recombinant host cells are also disclosed. Antibodies to the TDP-43 cellular binding protein are also described. The isolated nucleic acid sequences of the protein and its fragments are described in the construction of retroviral vectors.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: November 18, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard B. Gaynor, S.-H. Iqnatius Ou, Foon Kin Wu
  • Patent number: 5686264
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: November 11, 1997
    Assignee: Board of Regents, The University of Texas Sys
    Inventors: Richard B. Gaynor, Joseph A. Garcia, David Harrich
  • Patent number: 5677143
    Abstract: The invention relates to a cellular protein which is specific and has high affinity for nucleic acid sequences characteristic of an intact TAR RNA loop sequence of the HIV LTR TAR region. The invention also relates to a protein preparation having a protein of about 185 kD that is isolated from a mammalian cell nuclear extract preparation, most specifically a HeLa cell extract that is purified between 1,000-10,000 fold. The protein of about 185 kD is shown to regulate HIV viral gene expression by binding a TAR RNA region of an HIV LTR template, in the presence of a cofactor fraction (including at least a -100 kD cofactor), and a tat protein. A route for the development of immunodiagnostics for AIDS and related disorders may also be provided given the specific and high affinity of TRP-185 for HIV RNA.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: October 14, 1997
    Assignee: Board of Regents, University of TX System
    Inventors: Richard B. Gaynor, Foon K. Wu
  • Patent number: 5597895
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: January 28, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Richard B. Gaynor, Joseph A. Garcia, David Harrich
  • Patent number: 5534631
    Abstract: A gene encoding a cellular factor that binds to NFAT-like elements in the HIV-LTR has been obtained by .lambda.gt11 expression cloning using oligonucleotides corresponding to these binding motifs. This cDNA encodes a ubiquitously expressed 60 kD protein, termed interleukin binding factor (ILF), which binds specifically to such purine rich motifs in the HIV-LTR. ILF also binds to similar purine-rich motifs in the IL-2 promoter, although with lower affinity than to HIV-LTR sequences. Sequence analysis reveals the ILF DNA binding domain to have strong homology with the recently described fork head DNA binding domain of the Drosophila homeotic protein, fork head, and a family of hepatocyte-nuclear factors, HNF-3. Other domains found in ILF include a nucleotide binding site, an N-glycosylation motif, a signal for ubiquitin-mediated degradation, and a potential nuclear localization signal.
    Type: Grant
    Filed: June 30, 1992
    Date of Patent: July 9, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ching Li, Richard B. Gaynor, Ajay Nirula
  • Patent number: 5350835
    Abstract: The invention relates to a cellular protein which is specific and has high affinity for nucleic acid sequences characteristic of an intact TAR RNA loop sequence of the HIV LTR TAR region. The invention also relates to a between 1,000-10,000-fold purified, about 185 kD protein preparation isolated from a mammalian cell nuclear extract preparation, most specifically a HeLa cell extract. The about 185 kD protein is shown to regulate HIV viral gene expression by binding a TAR RNA region of an HIV LTR template, in the presence of a cofactor fraction (including at least a.about.100 kD cofactor), and a tat protein. The TRP-185, having a molecular weight of about 185 kD protein may also provide a research tool in the study of viral and cellular gene expression. A route for the development of immunodiagnostics for AIDS and related disorders may also be provided given the specific and high affinity of TRP-185 for HIV RNA.
    Type: Grant
    Filed: November 5, 1991
    Date of Patent: September 27, 1994
    Assignee: Board of Regents, University of Texas
    Inventors: Richard B. Gaynor, Foon K. Wu